Given the association between incidental PDE5 inhibitor use and a reduction in cardiovascular mortality following myocardial ischemia in type II diabetics, we sought to determine whether activation of the PKG pathway, using the PDE5 inhibitor sildenafil to increase cGMP, was protective against Ca2+-dependent arrhythmias. The gene discussed is PDE5A; the disease is myocardial ischemia.